Formatech donates $308K in aseptic liquid fill and finish manufacturing services

Formatech continues its pledge to give back and make a difference in the biotechnology and pharmaceutical community with its Fillanthropy Program. Since the program’s inception, Formatech has donated $308K in aseptic liquid fill and finish manufacturing services to companies developing new drug therapies.

“We feel it is important to do our part to help new therapies like these reach the patients in need.”

Introduced in August 2009, Formatech’s Fillanthropy Program has awarded fills to GeoVax Labs for their HIV/AIDS vaccine, KAI Pharmaceuticals for their secondary hyperparathyroidism treatment and most recently to ViroMed for their vaccine targeting breast cancer. “Each of us either knows someone or has personally been touched by the impact of a chronic disease,” said Indu Isaacs, CEO of Formatech. “We feel it is important to do our part to help new therapies like these reach the patients in need.”

As an established cGMP contract manufacturer with over 16 years of service, Formatech understands its role in helping to fight disease. It is within this spirit that the Fillanthropy Program was created. “At Formatech, we envision a world where all companies with promising new drug therapies have the opportunity to conduct a full clinical development program,” said Jeffrey Bernard, Formatech’s Director of Business Development.

Source: Formatech

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
VANCE trial marks milestone in t cell therapy for solid tumors